News

The company says the financing proceeds will be used to complete a randomized Phase 2 trial of CRLX101 in non-small cell lung cancer, and to support other investigator-sponsored

The company entered a field-exclusive option agreement with Harvard University to negotiate a license under patent rights that cover prophylactic uses of a modified anthrax toxin protein. The

According to the company, the new protein products offer good taste besides being beneficial for health. The company says that currently there is a need for protein and

According to the company, Truvada once approved would be the first agent indicated for uninfected individuals to reduce the risk of acquiring HIV through sex, a prevention approach

The facility in Nansha operates two small scale trains supplying clinical material, three large scale API trains for metric tons, and cGMP laboratories to meet gram-scale demands. The

As per the terms of the collaboration, Novozymes receives non-exclusive license to use MorphoSys’s Slonomics technology to develop novel products within the industrial biotechnology sector. The Advanced Protein

Enlight emphasizes on areas including molecular imaging, biologics, drug formulation delivery methods, besides novel chemistries, production technologies, biomarkers and drug safety. Enlight CEO Michelle Browner said the company

The FDA has also granted the company’s request for six-month Priority Review of Kalydeco, acts by targeting the defective protein that causes CF. The move follows the results

In July 2010, Servier and Galapagos collaborated to develop new medicines for the treatment of osteoarthritis (OA). Galapagos is responsible for the discovery and development of new candidate